Rite Aid to leverage RangeMe tech platform for product sourcing
SAN FRANCISCO — Rite Aid plans to leverage RangeMe, an online platform that streamlines new product discovery between suppliers and retailers, to scale its product innovation efforts.
“We strive to provide a tremendous in-store experience for our customers and that starts with our product offerings,” said Bill Bergin, Group VP of health and beauty at Rite Aid. “With RangeMe, we can now scale our discovery efforts and continue to source products that are unique and meaningful for our customers.”
Rite Aid’s category buying teams will now have faster access to source trending consumer-ready products, according to RangeMe.
“Consumers are open to trying new brands as trends are becoming the primary driver of purchasing decisions,” said Nicky Jackson, founder and CEO at RangeMe. “RangeMe looks forward to working with the Rite Aid team and supporting them in their efforts to bring unique products to their customers and differentiate their brand.”
San Francisco–based RangeMe offers buyers a platform that, according to RangeMe, gives suppliers increased control of the marketing of their products as well as greater access to retail buyers. In the past year, RangeMe has grown to more than 70,000 suppliers and more than 250,000 active products across all categories.
Octapharma gets FDA approval for new product strengths of NUWIQ
HOBOKEN, N.J. — Octapharma USA today announced that the U.S. Food and Drug Administration has approved new product strengths for NUWIQ. The move potentially reduces the number of vials needed for hemophilia A patients, the company said.
The agency approved new-single dose vial strengths of 2500-, 3000- and 4000-IU, which will be available for ordering in the United States starting Sept. 2017. These new vial strengths will be provided in addition to the already available strengths of 250-, 500-, 1000- and 2000 IU. NUWIQ is the only recombinant Factor VIII providing patients a wide array of vials with the lowest diluent volume of 2.5ml, the company added.
NUWIQ anti-hemophilic factor (recombinant) lyophilized powder for solution for intravenous injection is a recombinant anti-hemophilic factor indicated in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes; perioperative management of bleeding; and routine prophylaxis to reduce the frequency of bleeding episodes.
“The new vial options will benefit patients, physicians and healthcare professionals by providing greater treatment flexibility and convenience,” said Flemming Nielsen, Octapharma USA president. “The variety of vial options will be particularly beneficial to patients who previously may have needed more than one of the lower-strength vials. The availability of the new vial strengths further illustrates Octapharma’s unwavering commitment to the Hemophilia A community.”
The additional vial strengths offer benefits beyond potentially reducing the number of vials used per patient. The new vial sizes may benefit heavier patients who could use fewer product vials and, in some cases, just one vial, according to the company. More NUWIQ vial options will increase dosing flexibility by allowing physicians to select various vial combinations to align closer to the prescribed dose. The new vial sizes could be particularly beneficial to patients treated with NUWIQ utilizing a pharmacokinetic-guided personalized prophylaxis approach — wherein the dosing is further optimized compared with standard prophylaxis.
Amneal launches generic form of Tamiflu
BRIDGEWATER, N.J. — Amneal Pharmaceuticals has launched oseltamivir phosphate capsules, USP, in three strengths: 30-mg, 45-mg and 75-mg. The Amneal generic is an AB-rated therapeutic equivalent to Tamiflu. Each strength is available in 10-count blister dose-packs.
“Flu season is closer than we realize,” said Jim Luce, Amneal EVP, sales and marketing. “Amneal strives to assist healthcare providers and their patients by providing more affordable and greater access to treatment with our generic medication.”
Manufactured in the recently expanded Amneal facility in Brookhaven, N.Y., oseltamivir capsules began shipping July 11 from the company’s Glasgow, Ky., distribution center and can be purchased through major wholesalers and distributors. Annual U.S. sales of Tamiflu were $444 million according to May 2017 QuintilesIMS market data.